FOLH1 and prostate cancer: Due to its overexpression on the surface of prostate cancer cells and its extracellular binding pocket for small-molecule ligands, glutamate carboxypeptidase II (GPII), also known as prostate-specific membrane antigen (PSMA), is a relatively novel effective target for molecular imaging and radioligand therapy (RLT) in prostate cancer [1].